NVCT
Nuvectis Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.00
+2.90%2
Insider buys (3m)
0
Insider sells (3m)
$1.2M
Net value (3m)
+31.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 5, 2026 | Carson Michael J. · officer: Vice President, Finance | A-Award | 30,000 | $0.00 |
| Jul 1, 2026 | Mosseri Marlio Charles · 10 percent owner | Purchase | 50,000 | $18 |
| Jul 1, 2026 | BENTSUR RON · director, 10 percent owner, officer: Chairman & CEO | Purchase | 12,500 | $20 |
| Jun 12, 2026 | Hoberman Kenneth · director | A-Award | 35,000 | $0.00 |
| Jun 12, 2026 | Oliviero James F III · director | A-Award | 35,000 | $0.00 |
| Jun 12, 2026 | Sanchez Juan · director | A-Award | 35,000 | $0.00 |
| Jun 12, 2026 | Kaplan Matthew L. · director | A-Award | 35,000 | $0.00 |
| Jan 9, 2026 | Carson Michael J. · officer: Vice President, Finance | A-Award | 61,200 | $0.00 |
| Jan 9, 2026 | Poradosu Enrique · officer: Chief Science & Business Off | A-Award | 150,000 | $0.00 |
| Jan 9, 2026 | Shemesh Shay · officer: Chief Dev. & Ops. Officer | A-Award | 150,000 | $0.00 |
| Jan 9, 2026 | BENTSUR RON · director, 10 percent owner, officer: Chairman & CEO | A-Award | 150,000 | $0.00 |
| Nov 6, 2025 | Kaplan Matthew L. · director | Purchase | 11,000 | $5.84 |
| Nov 6, 2025 | BENTSUR RON · director, 10 percent owner, officer: Chairman & CEO | Purchase | 5,000 | $5.72 |
| Nov 6, 2025 | Sanchez Juan · director | Purchase | 13,000 | $5.79 |
| Oct 31, 2025 | Sanchez Juan · director | A-Award | 30,000 | $0.00 |
| Oct 29, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 72,836 | $6.28 |
| Oct 29, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 35,034 | $6.15 |
| Oct 29, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 46,900 | $6.06 |
| Jun 24, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 5,603 | $7.99 |
| Jun 20, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 28,043 | $8.05 |
| Jun 20, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 5,399 | $8.11 |
| Jun 12, 2025 | Kaplan Matthew L. · director | A-Award | 30,000 | $0.00 |
| Jun 12, 2025 | Oliviero James F III · director | A-Award | 30,000 | $0.00 |
| Jun 12, 2025 | Hoberman Kenneth · director | A-Award | 30,000 | $0.00 |
| May 13, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 21,167 | $8.11 |
| May 12, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 5,395 | $8.98 |
| May 12, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 9,817 | $8.90 |
| May 12, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 9,850 | $8.95 |
| May 12, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 2,400 | $8.97 |
| May 12, 2025 | Mosseri Marlio Charles · 10 percent owner | Purchase | 100 | $8.71 |
Institutional positioning
13F filings over the trailing two quarters
New 46Increased 55Reduced 23Sold out 6
| Filer | Action | Shares | Filed |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | New Position | 1,550,000 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 1,001,285 | Aug 7, 2026 |
| PERCEPTIVE ADVISORS LLC | New Position | 1,000,000 | Aug 14, 2026 |
| Soleus Capital Management, L.P. | New Position | 1,000,000 | Aug 11, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 872,482 | Aug 13, 2026 |
| IRIDIAN ASSET MANAGEMENT LLC/CT | Increased | 777,078 | Jul 29, 2026 |
| BLACKROCK, INC. | Reduced | 764,441 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 659,879 | May 15, 2026 |
| IRIDIAN ASSET MANAGEMENT LLC/CT | Increased | 651,757 | Apr 24, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 432,273 | Aug 12, 2026 |
| Occam Crest Management LP | Increased | 407,147 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 384,105 | May 15, 2026 |
| SPHERA FUNDS MANAGEMENT LTD. | New Position | 382,945 | Aug 14, 2026 |
| BALDWIN WEALTH PARTNERS LLC/MA | Increased | 382,015 | Jul 14, 2026 |
| BALDWIN BROTHERS LLC/MA | Reduced | 378,625 | Apr 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 5, 2026